Tech Company Financing Transactions
Ardelyx Funding Round
Ardelyx closed a $30 million Series B investment round on 8/31/2011. Backers included Amgen Ventures, New Enterprise Associates and Presidio Partners.
Transaction Overview
Company Name
Announced On
8/31/2011
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series B
Investors
Proceeds Purpose
The proceeds of the financing will be used to advance Ardelyx's pipeline that includes three product candidates: a clinical stage product, RDX5791, being evaluated in constipation-predominant irritable bowel syndrome (IBS-C) and in the prevention of excess dietary sodium absorption, and two preclinical products, RDX002 in chronic kidney disease and RDX009 in type 2 diabetes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
34175 Ardenwood Blvd. 200
Fremont, CA 94555
USA
Fremont, CA 94555
USA
Phone
Website
Email Address
Overview
Ardelyx develops novel oral therapeutics to treat mineral metabolism and metabolic disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mike Raab
Chief Financial Officer
Mark Kaufmann
VP - Bus. Development
David Rosenbaum
VP - Operations
Jeffrey Jacobs
Browse more venture capital transactions:
Prev: 8/31/2011: Cellerant Therapeutics venture capital transaction
Next: 8/31/2011: CiDRA venture capital transaction
Share this article
About Our VC Transactions Data
We record funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs